Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Nyse  -  01:00 2022-11-25 pm EST
76.36 USD   +0.59%
11/15Insider Sell: Edwards Lifesciences
MT
11/03Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $73 From $97, Maintains Neutral Rating
MT
11/01Edwards Lifesciences Launches $750 Million Accelerated Share Repurchase Agreement
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Edwards Lifesciences Corporation Announces Results from CLASP IID

09/17/2022 | 11:30am EST

Edwards Lifesciences Corporation announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR). Results from the CLASP IID pivotal trial were presented as a late-breaking clinical science session at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, and published simultaneously in JACC: Cardiovascular Interventions.

Patients enrolled in the CLASP IID pivotal trial had severe symptomatic DMR and were determined to be at prohibitive surgical risk. The CLASP IID trial met its primary safety and effectiveness endpoints, with the PASCAL system demonstrating non-inferiority for safety and effectiveness compared to the MitraClip device. The PASCAL device showed: Low composite major adverse event rate of 3.4 percent at 30 days, and Significant and sustained MR reduction with 97.7 percent of patients achieving MR =2+ at six months.

The PASCAL system further demonstrated significant and sustained MR =1+ with 83.7 percent of patients at MR =1+ at six months. PASCAL system results also showed favorable ventricular remodeling with improved stroke volume, and patients receiving the PASCAL system experienced significant improvements in functional capacity and quality of life. The CLASP IID trial is a prospective randomized controlled trial comparing the safety and effectiveness of the PASCAL system to the MitraClip system.

Results were reported on 180 patients with 2:1 randomization (117 PASCAL /63 MitraClip), with echo core lab adjudication. The trial included 43 sites in the US, Canada and Europe, with most clinical operators new to using the PASCAL system and all having experience with the MitraClip system. Additional data presentations for the company during TCT 2022 include: The PASCAL IID Registry: A Prospective Registry for Transcatheter Edge-to-Edge Repair in Prohibitive Risk Patients With Degenerative Mitral Regurgitation and Complex Mitral Valve Anatomy (Sept.

17) – Late-Breaking Presenter: Jörg Hausleiter. Deep Dive Session: Mitral TEER = CLASP IID Trials (Sept. 17) – Moderators: Megan Coylewright, Linda D. Gillam.

Discussants: Paul A. Grayburn, Konstantinos P. Koulogiannis, Raj Makkar, Jacob M. Mishell, Ralph Stephan von Bardeleben, Firas Zahr. Frequency and Safety of Bioprosthetic Valve Fracture in Patients Undergoing Valve in Valve TAVR for Failed Surgical Valves Using the SAPIEN 3/Ultra Valves: Insights From Real-World Data (Sept. 18) – Presenter: Santiago Garcia.

Cardiac Damage and Quality of Life After Aortic Valve Replacement: Results from the PARTNER Trials (Sept. 18) – Presenter: Philippe Genereux. Edwards is committed to transforming the treatment of patients with structural heart disease, supported by robust clinical evidence.

As part of Edwards' continued commitment to building a body of real-world evidence, patients receiving the PASCAL Precision therapy in the US will be enrolled in the TVT Registry for five years. The PASCAL Precision system is one of multiple transcatheter repair or replacement therapies in development by Edwards and the company's first approved transcatheter therapy for DMR in the US. The PASCAL system first received CE Mark in Europe in 2019, and the PASCAL Precision system received CE Mark in 2022.


ę S&P Capital IQ 2022
All news about EDWARDS LIFESCIENCES CORPORATION
11/15Insider Sell: Edwards Lifesciences
MT
11/03Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $73 From $97, Maintains N..
MT
11/01Edwards Lifesciences Launches $750 Million Accelerated Share Repurchase Agreement
MT
11/01Edwards Lifesciences Corp : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/01Edwards lifesciences announces $750 million accelerated share repurchase
PR
10/31Raymond James Lowers Edwards Lifesciences' Price Target to $85 From $120, Maintains Out..
MT
10/31North American Morning Briefing: Futures Pull -3-
DJ
10/28Health Care Up on Earnings Optimism -- Health Care Roundup
DJ
10/28EDWARDS LIFESCIENCES CORP Management's Discussion and Analysis of Financial Condition ..
AQ
10/28Tranche Update on Edwards Lifesciences Corporation ..
CI
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2022 5 360 M - -
Net income 2022 1 495 M - -
Net cash 2022 1 120 M - -
P/E ratio 2022 32,1x
Yield 2022 -
Capitalization 47 210 M 47 210 M -
EV / Sales 2022 8,60x
EV / Sales 2023 7,90x
Nbr of Employees 15 700
Free-Float 95,1%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Last Close Price 76,36 $
Average target price 95,45 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EDWARDS LIFESCIENCES CORPORATION-41.06%47 210
THERMO FISHER SCIENTIFIC-17.38%217 219
DANAHER CORPORATION-18.84%194 395
INTUITIVE SURGICAL, INC.-26.40%93 693
BOSTON SCIENTIFIC CORPORATION3.32%63 237
SIEMENS HEALTHINEERS AG-21.67%59 953